Efficacy of doluxetine add on conventional treatment in inflammatory bowel disease patients, on depression, anxiety quality of life and severity of symptoms

We assessed the efficacy of drug duloxetine or placebo on anxiety, depression, severity of symptoms and quality of life in patients with inflammatory bowel disease. Inclusion criteria include men and women age 18–65 years old who were diagnosed with inflammatory bowel disease with no flair up through past six months and exclusion criteria include lifetime bipolar, psychotic, or obsessive-compulsive disorder; substance use disorders, major depressive disorder or anxiety disorders in the past 6 months and treatment with any psychotropic medication within seven days of beginning of study. The 40 subjects were selected from patients who referred to gastrointestinal clinic of Alzahra Hospital (Isfahan, Iran) during 2013 to 2014. After screening the subjects were divided into two groups of duloxetine and placebo randomly.The study was performed in 12 weeks. In drug group, duloxetine started with 30 mg once a day for 1 week, and then 60 mg once a day for the next 11 weeks. In placebo group the subjects received placebo in the same form and packages as duloxetine. We assessed anxiety, depression, severity of symptoms and quality of life in subjects before and just after the treatment with Hospital Anxiety and Depression Scale, Lichtiger Colitis Activity Index and World Health Organization Quality of Life Instruments respectedly.

Isfahan University of Medical Sciences